MediXall (MDXL) Cost of Revenue (2023 - 2024)
MediXall's Cost of Revenue history spans 2 years, with the latest figure at $16558.0 for Q3 2024.
- For Q3 2024, Cost of Revenue fell 73.76% year-over-year to $16558.0; the TTM value through Sep 2024 reached $129969.0, down 30.9%, while the annual FY2023 figure was $236509.0, N/A changed from the prior year.
- Cost of Revenue reached $16558.0 in Q3 2024 per MDXL's latest filing, up from $14587.0 in the prior quarter.
- In the past five years, Cost of Revenue ranged from a high of $89401.0 in Q1 2023 to a low of $14587.0 in Q2 2024.